Sumatriptan and Application site erythema - a phase IV clinical study of FDA data

Summary:

Application site erythema is reported as a side effect among people who take Sumatriptan (sumatriptan succinate), especially for people who are female, 40-49 old, also take Oxytrol For Women, and have Headache.

The phase IV clinical study analyzes which people have Application site erythema when taking Sumatriptan. It is created by eHealthMe based on reports of 17,179 people who have side effects when taking Sumatriptan from the FDA, and is updated regularly.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

What is Application site erythema?

Application site erythema (redness of the skin at application site) is found to be associated with 676 drugs and 950 conditions by eHealthMe. Check the latest studies of Application site erythema.

On Jul, 12, 2026

17,179 people reported to have side effects when taking Sumatriptan.
Among them, 11 people (0.06%) have Application site erythema.

Could Sumatriptan cause Application site erythema?

Among these 11 people:

What is the gender of people who have Application site erythema when taking Sumatriptan? *

female: 100 %
male: 0.0 %

What is the age of people who have Application site erythema when taking Sumatriptan? *

What are other drugs people take besides Sumatriptan? *

What are other side effects people have besides Application site erythema? *

Application Site Pruritus (application site severe itching of the skin): 5 people, 45.45%
Application Site Swelling: 3 people, 27.27%
Muscle Function Loss: 2 people, 18.18%
Inflammation: 2 people, 18.18%
Drug Ineffective: 2 people, 18.18%
Application Site Exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface): 2 people, 18.18%
Application Site Irritation: 2 people, 18.18%
Skin Irritation: 1 person, 9.09%
Application Site Papules (solid elevation of skin with no visible fluid at application site): 1 person, 9.09%
Application Site Burn: 1 person, 9.09%

What are the existing conditions these people have? *

Headache (pain in head): 4 people, 36.36%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 18.18%
Urination - Excessive At Night: 1 person, 9.09%
Precancerous Skin Lesion: 1 person, 9.09%
Micturition Urgency (urgency to pass the urine): 1 person, 9.09%
Menopausal Symptoms: 1 person, 9.09%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 1 person, 9.09%
Hypersensitivity: 1 person, 9.09%
Hot Flush (sudden feelings of heat): 1 person, 9.09%
High Blood Cholesterol: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan and have Application site erythema?

- Check whether Application site erythema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sumatriptan:

Sumatriptan (18,159 reports)

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site erythema:

Application site erythema (676 drugs)

Browse all the conditions that are associated with Application site erythema:

Application site erythema (950 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Sumatriptan) and Sumatriptan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.